SCHEMBL24265441

SCHEMBL24265441

N#Cc1ccc(COc2nn(C3CCNCC3)cc2C(F)(F)F)c(F)c1

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAP4K3 Q8IVH8 3/20 0.40
KCNH2 Q12809 1/20 0.39
GPR119 Q8TDV5 1/20 0.39
HTR6 P50406 1/20 0.39
KDM1A O60341 4/20 0.38
TLR8 Q9NR97 2/20 0.36
KHK P50053 2/20 0.36
ALK Q9UM73 2/20 0.35
SLC6A2 P23975 3/20 0.34
SLC6A4 P31645 3/20 0.34
SLC6A3 Q01959 1/20 0.34
MAOB P27338 1/20 0.34
CTSS P25774 1/20 0.34
CTSK P43235 1/20 0.34
INPPL1 O15357 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24266549 0.89 HTR6 (0.41) MAP4K3KCNH2GPR119HTR6KDM1A
SCHEMBL24265686 0.87 KDM1A (0.44) MAP4K3KCNH2GPR119HTR6KDM1A
SCHEMBL29574126 0.87 KDM1A (0.44) MAP4K3KCNH2GPR119HTR6KDM1A
SCHEMBL24265925 0.86 INPPL1 (0.40) MAP4K3KCNH2GPR119HTR6KDM1A
SCHEMBL29574548 0.86 INPPL1 (0.40) MAP4K3KCNH2GPR119HTR6KDM1A
SCHEMBL24265824 0.86 HTR6 (0.44) MAP4K3KCNH2GPR119HTR6KDM1A
SCHEMBL24266542 0.85 HTR6 (0.41) MAP4K3KCNH2GPR119HTR6KDM1A
SCHEMBL29573778 0.85 HTR6 (0.46) MAP4K3KCNH2GPR119HTR6KDM1A
SCHEMBL24265507 0.85 HTR6 (0.46) MAP4K3KCNH2GPR119HTR6KDM1A
SCHEMBL29574663 0.85 HTR6 (0.41) MAP4K3KCNH2GPR119HTR6KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322744-A1 COMPOUNDS AS GLP-1R AGONISTS TERNS PHARMACEUTICALS, INC. 2023-10-12 US disclosed
US-20230322744-A1 COMPOUNDS AS GLP-1R AGONISTS TERNS PHARMACEUTICALS, INC. 2023-10-12 US disclosed
CN-116507326-A Compounds as GLP-1R agonists 拓臻制药公司 2023-07-28 CN disclosed
EP-4199919-A1 COMPOUNDS AS GLP-1R AGONISTS Terns Pharmaceuticals, Inc. (US) 2023-06-28 EP disclosed
WO-2022040600-A1 COMPOUNDS AS GLP-1R AGONISTS TERNS PHARMACEUTICALS, INC. (US) 2022-02-24 WO disclosed
WO-2022040600-A1 COMPOUNDS AS GLP-1R AGONISTS TERNS PHARMACEUTICALS, INC. (US) 2022-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322744-A1 COMPOUNDS AS GLP-1R AGONISTS GLP1R, GIPR, GCGR MAP4K3 1285/4885KCNH2 3089/4885GPR119 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.